Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data
ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.
The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings
ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.
Vaping Associated with Increased Risk of Heart Failure, According to New Research
ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.
CAC Progression in Postmenopausal Women Found Double that of Men in New Research
ACC.24: Loss of estrogen's cardioprotective effect could account for the 2-fold greater increase in CAC score seen among postmenopausal women compared with men.
Young Adults Prescribed ADHD Stimulants May Face Higher Risk of Cardiomyopathy
ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.
Icosapent Ethyl Reduces MACE Across Range of Baseline Lp(a): REDUCE-IT Analysis
ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.
Remotely Delivered Lipid Lowering Program Results in Sustained Target LDL-C Levels in High-Risk Population
ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.
Phase 3 Findings on Neffy for Pediatric Patients with Severe Allergies: A Conversation with Motohiro Ebisawa, MD, PhD
Dr Ebisawa details the findings he recently presented at the 2024 AAAAI annual meeting, including adverse events and next steps for the study.
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers
AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.
